CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
Regenxbio aligns with FDA on next steps for potential accelerated approval of Navsunli gene therapy